1. Mishra et al. Engineering solid lipid nanoparticles for improved drug delivery: promises and challenges of translational research. Drug Deliv. and Transl. Res, 2: 238-253; 2012.
2. Bethune et al., The role of drug-lipid interactions on the disposition of liposome-formulated opioid analgesics in vitro and in vivo. Anesth Analg. 93(4):928-33; 2001.
3. Guarnieri et al.,Safety and efficacy of buprenorphine for analgesia in laboratory mice and rats. Lab Animal, 41(11): 337-343; 2012.
4. Levinson BL, Leary SL, Bassett BJ, Cook CJ, GormanGS, Coward LU. Pharmacokinetic and Histopathologic Study of an Extended-Release, Injectable formulation of Buprenorphine in Sprague-Dawley Rats. J Am Assoc Lab Anim Sci. Jan 1, 61(1): 81-8; 2022.
5. Fidelis’ postmarketing surveillance database.
6. Fabian NJ et al. Evaluation and comparison of pharmacokinetic profiles and safety of two extended-release buprenorphine formulations in common marmosets (Callithrix jacchus). Scientific Reports, 13, 11864; 2023.
7. Klein H. et al. A pharmacokinetic study of extended-release buprenorphine in Cynomolgus monkeys (m.fascicularis). Journal of Medical Primatology. 52(6):369-373; 2023.
8. Williams W et al. Pharmacokinetics of sustained-release buprenorphine in adult baboons (Papio Anubis). 2021 National Meeting of the Am Assoc for Lab Anim Sci (virtual).
9. Katzenbach JE, Wittenburg LA, Allweiler SI, Gustafson DL, Johnson MS. Pharmacokinetics of single-dose buprenorphine, butorphanol, and hydromorphone in the domestic ferret (Mustela putorius furo). J Exotic Pet Med 27:95-102; 2018.
10. Chan G et al. Assessment of the Safety and Efficacy of Pre-emptive Use of Extended-release Buprenorphine for Mouse Laparotomy. J Am Assoc Lab Anim Sci 99(99): 1-7;2022.
11. Traul KA et al. Safety studies of post-surgical buprenorphine therapy for mice. Lab Anim. 49(2):100-110;2015.
12. Cowan A et al. Lack of adverse effects during a target animal safety trial of extended-release buprenorphine in Fisher 344 rats. Nature America, Inc. Jan Vol 45(1):28-34; 2016.
13. Bowie AR et al. Pharmacokinetics of Extended-release Buprenorphine in Mongolian Gerbils (Meriones unguiculatus). J Am Assoc Lab Anim Sci: 62 (6): 538-544; 2023.
14. Zanetti AS et al. Pharmacokinetics and adverse effects of 3 sustained-release buprenorphine dosages in healthy guinea pigs. J Am Assoc Lab Anim Sci 56 (6): 768-778; 2017.
15. Fox L et al. Analgesic Efficacy and Safety of Buprenorphine in Chinchillas (Chinchilla lanigera). J Am Assoc Lab Anim Sci 57 (3): 286-290; 2018.
16. Alamaw ED et al. Extended-release Buprenorphine, an FDA indexed Analgesic, Attenuates Mechanical Hypersensitivity in Rats (Rattus norvegicus). J Am Assoc Lab Anim Sci. 61 (1): 81-88; 2022.
17. Oliver VL et al. Evaluation of pain assessment techniques and analgesic efficacy in a female guinea pig model of surgical pain. Am Assoc Lab Anim Med. 56 (4): 425-435; 2017.
18: Hutson CL et al. Analgesia during Monkeypox Virus Experimental Challenge Studies in Prairie Dogs (Cynomys ludovicianus). J Am Assoc Lab Anim Sci. 58 (4):485-500; 2019.
19. Farkas MR, Dorn S, Muller L, et al. Pharmacokinetics, Fecal Output, and Grimace Scores in Rabbits Given Long-Acting Buprenorphine or Fentanyl for Postsurgical Analgesia. J Am Assoc Lab Anim Sci.; 2024.
20. New Zealand white rabbits receiving 0.15 mg/kg and 0.3 mg/kg SQ Ethiqa XR. Unpublished study 2021. Data on file.
21. Nair AB, Jacob S. A simple practice guide for dose conversion between animals and human. J Basic Clin Pharm. 7(2):27-31; 2016.
22. Food and Drug Administration. FDA Guidance for Industry Estimating the Maximum Safe Starting Dose in Initial Clinical Trials for Therapeutics in Adult Healthy Volunteers. July 2005.